Nalm-6

The Nalm-6 cell line, derived from the peripheral blood of a patient with B-cell precursor acute lymphoblastic leukemia (ALL), has become a critical tool in leukemia research. The human cell line Nalm 6 encapsulates the biological characteristics of B-cell ALL, providing a unique window into the disease's genomic landscape, including genome instability and DNA repair mechanisms.

The utility of Nalm-6 cells extends to studying the efficacy of available therapeutic targets and existing resistance mechanisms. The cell line's sensitivity to cytotoxic agents and its role in elucidating the homologous recombination (HDR) repair functions are of particular interest, especially concerning the HDR cells' ability to correct DNA damage.

The Nalm6 cell line is a reliable model for studying the complex nature of acute leukemia. It facilitates research into the gene expression profiles involved in glycolysis, lipid and carbohydrates metabolism, and the mTORC1 pathway, highlighting the metabolic reprogramming in leukemia cells. Furthermore, the cell line's application in reverse genetics and whole transcriptome analysis aids in dissecting the intricate molecular networks driving leukemia progression and resistance.

Research utilizing the Nalm-6 cell line, including studies on clonal variants like clone G5 and resistant cell lines such as those with a high HPRT mutation frequency or C9 with resistance index, provides insights into leukemia's heterogeneity. The exploration of leukemia dynamics, especially in the context of glucocorticoid resistance and MSH2 expression, underscores the potential for developing more targeted and effective treatments for ALL.

In summary, the Nalm-6 cell line is a pivotal resource in leukemia research, offering profound insights into B-cell ALL through its applications in studying genomic instability, DNA repair mechanisms, therapeutic target efficacy, resistance mechanisms, and the underlying molecular pathways influencing leukemia's complex biology and heterogeneity.